Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice

References

• Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas Principles and practice of pediatric oncology. Eds: Pizzo PA, Poplack DG, 5th ed, Lippincott. 2006; 971-1002.
   Google Scholar
• Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol 2002; 20:2672 - 9; http://dx.doi.org/10.1200/JCO.2002.03.137; PMID: 12039929
   PubMed Web of Science ®Google Scholar
• Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66:6936 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-05-4578; PMID: 16849537
   PubMed Web of Science ®Google Scholar
• Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, Rauscher FJ 3rd. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995; 15:1522 - 35; PMID: 7862145
   PubMed Web of Science ®Google Scholar
• Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006; 66:4742 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-05-4292; PMID: 16651427
   PubMed Web of Science ®Google Scholar
• Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, Purgato S, Missiaglia E, Tortori A, Renshaw J, et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res 2012; 18:796 - 807; http://dx.doi.org/10.1158/1078-0432.CCR-11-1981; PMID: 22065083
   PubMed Web of Science ®Google Scholar
• Toffolatti L, Frascella E, Ninfo V, Gambini C, Forni M, Carli M, Rosolen A. MYCN expression in human rhabdomyosarcoma cell lines and tumour samples. J Pathol 2002; 196:450 - 8; http://dx.doi.org/10.1002/path.1068; PMID: 11920742
   PubMed Web of Science ®Google Scholar
• Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res 2007; 635:90 - 104; http://dx.doi.org/10.1016/j.mrrev.2006.10.004; PMID: 17134937
   PubMed Web of Science ®Google Scholar
• Bertl E, Bartsch H, Gerhäuser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther 2006; 5:575 - 85; http://dx.doi.org/10.1158/1535-7163.MCT-05-0324; PMID: 16546971
   PubMed Web of Science ®Google Scholar
• Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhäuser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001; 276:32008 - 15; http://dx.doi.org/10.1074/jbc.M104794200; PMID: 11410599
   PubMed Web of Science ®Google Scholar
• Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 2006; 20:506 - 8; PMID: 16407454
   PubMed Web of Science ®Google Scholar
• Angeloni C, Leoncini E, Malaguti M, Angelini S, Hrelia P, Hrelia S. Modulation of phase II enzymes by sulforaphane: implications for its cardioprotective potential. J Agric Food Chem 2009; 57:5615 - 22; http://dx.doi.org/10.1021/jf900549c; PMID: 19456137
   PubMed Web of Science ®Google Scholar
• Conaway CC, Yang YM, Chung FL. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab 2002; 3:233 - 55; http://dx.doi.org/10.2174/1389200023337496; PMID: 12083319
   PubMed Web of Science ®Google Scholar
• Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov AV, Herr I. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 2011; 19:188 - 95; http://dx.doi.org/10.1038/mt.2010.216; PMID: 20940707
   PubMed Web of Science ®Google Scholar
• Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL. Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 2004; 15:5064 - 74; http://dx.doi.org/10.1091/mbc.E04-03-0184; PMID: 15356269
   PubMed Web of Science ®Google Scholar
• Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ, Choi KS. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 2006; 66:1740 - 50; http://dx.doi.org/10.1158/0008-5472.CAN-05-1568; PMID: 16452234
   PubMed Web of Science ®Google Scholar
• Nanni C, Di Leo K, Tonelli R, Pettinato C, Rubello D, Spinelli A, Trespidi S, Ambrosini V, Castellucci P, Farsad M, et al. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur J Nucl Med Mol Imaging 2007; 34:755 - 62; http://dx.doi.org/10.1007/s00259-006-0288-y; PMID: 17160412
   PubMed Web of Science ®Google Scholar
• Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 2007; 48:602 - 7; http://dx.doi.org/10.2967/jnumed.106.036608; PMID: 17401098
   PubMed Web of Science ®Google Scholar
• Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, Schäfer BW. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene 2010; 29:3942 - 52; http://dx.doi.org/10.1038/onc.2010.145; PMID: 20453878
   PubMed Web of Science ®Google Scholar
• Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther 2004; 3:1239 - 48; PMID: 15486191
   PubMed Web of Science ®Google Scholar
• Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 2004; 25:83 - 90; http://dx.doi.org/10.1093/carcin/bgg178; PMID: 14514658
   PubMed Web of Science ®Google Scholar
• Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 2006; 55:53 - 62; http://dx.doi.org/10.1207/s15327914nc5501_7; PMID: 16965241
   PubMed Web of Science ®Google Scholar
• Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002; 1:97 - 104; PMID: 12170781
   PubMed Web of Science ®Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O’Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28:2839 - 46; http://dx.doi.org/10.1200/JCO.2009.25.1991; PMID: 20458040
   PubMed Web of Science ®Google Scholar
• Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012; 11:3 - 13; http://dx.doi.org/10.1158/1535-7163.MCT-11-0434; PMID: 22234808
   PubMed Web of Science ®Google Scholar